ArticleScientific reports2026
Thermally enhanced efficacy of chemotherapy potentiates cisplatin-based hyperthermic intraperitoneal chemotherapy in ovarian cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Ovarian cancer is the deadliest gynecological malignancy, with high relapse and drug resistance rates. Hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery and systemic chemotherapy has improved survival in patients with peritoneal metastases, though findings remain inconsistent. This study investigates whether the benefits of HIPEC are due to the additional chemotherapy or the combination with hyperthermia. High-grade and non-high-grade serous ovarian cancer cell lines were treated with carboplatin and paclitaxel. Additionally, the cells were treated with cisplatin at 37 to 43 °C for 90 min (HIPEC). Cell proliferation, colony formation, apoptosis, cell cycle and DNA damage were assessed by MTT, clonogenic assay, flow cytometry, western blot and γ-H2AX foci assay. High-grade serous cells were more sensitive to both carboplatin-paclitaxel and hyperthermia. Cisplatin demonstrated a temperature-dependent synergy with heat, resulting in increased DNA damage, apoptosis, and G2-arrest. Combining carboplatin and paclitaxel with hyperthermia plus cisplatin further reduced survival and increased cellular stress marker compared to carboplatin and paclitaxel alone. Hyperthermia significantly enhances cisplatin efficacy when added to carboplatin and paclitaxel pretreatment. This suggests that the addition of hyperthermia to cisplatin after carboplatin-paclitaxel is more effective than carboplatin-paclitaxel alone in both high-grade and non-high grade serous ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.